Investigational Therapy RHB-107 Holds Potential to Treat IBD, Other Disorders, RedHill Announces

Investigational Therapy RHB-107 Holds Potential to Treat IBD, Other Disorders, RedHill Announces
RedHill Biopharma is evaluating the potential of its proprietary therapy RHB-107 (upamostat, formerly known as Mesupron) to treat inflammatory digestive diseases and cancer, the company announced in a press release. Results of experimental studies show that WX-UK1, the active compound in RHB-107, efficiently inhibits five serine proteases called trypsin-3, trypsin-2, trypsin-1, matriptase-1, and trypsin-6. These enzymes

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *